NACE 47.59 in FR. Official registry identity, filed financial evidence and a rounded indicative valuation range on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
You have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for PERGASOL combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Operating as a business in NACE sector 47.59, PERGASOL is registered in France. The company was founded in 2012, incorporated as a 5710.
PERGASOL is listed in French National Business Register (RNE/INPI) under registry number 790050314. The public employee band is 02, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 47.59 band file annual accounts with INPI.
An indicative valuation band is available for PERGASOL, based on filed company accounts. A free account lets the visitor refine it with current data and build a five-year outlook.
The most recent annual filing covers 2024 (period end 2024-08-31).
This page is refreshed whenever new regulator-filed data for PERGASOL becomes available, consolidated into a single audit-grade view.
Public regulator-filed figures across 8 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Aug 2025 | - | - | €1,243,034 | €793,181 | - |
| 202431 Aug 2024 | €2,606,915 | - | €1,414,908 | €1,023,652 | - |
| 202331 Aug 2023 | - | - | €990,813 | €821,582 | - |
| 202231 Aug 2022 | - | - | €978,617 | €728,215 | - |
| 202131 Aug 2021 | - | - | €792,884 | €512,283 | - |
| 202031 Aug 2020 | - | - | €559,930 | €331,033 | - |
| 201731 Aug 2017 | €511,298 | - | €259,571 | €89,552 | - |
| 201631 Aug 2016 | €362,010 | - | €122,679 | €50,482 | - |
PERGASOL was founded in 2012 and is registered with French National Business Register (RNE/INPI), incorporated as a 5710.
PERGASOL is registered under NACE 47.59: NACE 47.59. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-08-31), publicly available via French National Business Register (RNE/INPI).
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for PERGASOL may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
